Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Single ascending dose study of ACT-280778 in male volunteers

Trial Profile

Single ascending dose study of ACT-280778 in male volunteers

Phase of Trial: Phase I

Latest Information Update: 01 Feb 2014

At a glance

  • Drugs ACT 280778 (Primary)
  • Indications Hypertension
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 22 Mar 2013 New trial record
    • 09 Mar 2013 Results presented at the 114th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top